49 related articles for article (PubMed ID: 35141850)
1. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
2. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
[TBL] [Abstract][Full Text] [Related]
3. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
4. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
6. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.
Zhao J; Zhou L; Zhang Y; Cheng J; Zeng Y; Li X
Sci Rep; 2024 Apr; 14(1):8161. PubMed ID: 38589540
[TBL] [Abstract][Full Text] [Related]
7. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
Yamada S; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Uemura H; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mizuno S; Mochida S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38517681
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B: A Meta-analysis.
Chen L; Jiang Q; Chen X
Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38551440
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.
Cheng PN; Yu ML
Clin Mol Hepatol; 2024 Apr; 30(2):144-146. PubMed ID: 38373418
[No Abstract] [Full Text] [Related]
10. Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment.
Hong H; Cho M; Lim C; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Aliment Pharmacol Ther; 2024 Feb; 59(4):515-525. PubMed ID: 38009290
[TBL] [Abstract][Full Text] [Related]
11. Which form of tenofovir should be used worldwide: TDF or TAF?
Hill A
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38606797
[No Abstract] [Full Text] [Related]
12. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Tian F; Houle SKD; Alsabbagh MW; Wong WWL
Pharmacoeconomics; 2020 Feb; 38(2):181-192. PubMed ID: 31691902
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
Zhang C; Ke W; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Drug Des Devel Ther; 2016; 10():897-910. PubMed ID: 27041994
[TBL] [Abstract][Full Text] [Related]
17. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
Tong K; Chen M; Wang D; Dai H; Peng J; Zhang J; Zhou J; Chang Y; Huang W
Eur J Clin Pharmacol; 2024 Mar; 80(3):335-354. PubMed ID: 38197944
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
